Navigation Links
MAP Pharmaceuticals to Present at Upcoming Investor Conferences
Date:4/25/2008

MOUNTAIN VIEW, Calif., April 25 /PRNewswire-FirstCall/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced that the company will present at the following upcoming investor conferences on April 30th and May 6th, 2008:

Morgan Stanley Global Healthcare Conference, Key Biscayne, FL

Wednesday, April 30, 2008

9:10 am, Eastern Time

Deutsche Bank 33rd Annual Health Care Conference, Boston, MA

Tuesday, May 6, 2008

10:10 am, Eastern Time

A live webcast of the presentations will be available on the Investor Relations section of MAP Pharmaceuticals' website at http://www.mappharma.com. A replay will also be available within 24 hours for seven days following the presentation.

About MAP Pharmaceuticals, Inc.

MAP Pharmaceuticals develops and plans to commercialize new therapies for children and adults who suffer from chronic conditions that it believes are not adequately treated by currently available medicines. The company applies its proprietary inhalation technologies to enhance the therapeutic benefits and commercial attractiveness of proven drugs while minimizing risk by capitalizing on their known safety, efficacy and commercialization history. MAP Pharmaceuticals has two drug candidates, Unit Dose Budesonide and MAP0004, in late stage development for the potential treatment of pediatric asthma and migraine respectively. MAP Pharmaceuticals' pipeline also includes a drug candidate in early clinical development for the treatment of asthma and chronic obstructive pulmonary disease.

Additional information about MAP Pharmaceuticals can be found at http://www.mappharma.com<
'/>"/>

SOURCE MAP Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Agreement Executed for Amneal Pharmaceuticals to Acquire the Assets of Interpharm Holdings
2. Lotus Pharmaceuticals, Inc. Announces Resignation of Director Mel Rothberg
3. Onyx Pharmaceuticals to Present at Morgan Stanley Global Healthcare Unplugged Conference
4. Antipodean Pharmaceuticals Announces Results of Phase 2 Study of Lead Compound MitoQ(R)
5. Jazz Pharmaceuticals to Present at Morgan Stanley Conference
6. Aida Pharmaceuticals, Inc. Announces Availability of Downloadable Corporate Synopsis on its Website
7. ISTA Pharmaceuticals Announces Conference Call and Webcast of First Quarter 2008 Financial Results
8. Law Offices of Howard G. Smith Announces 21 Days Remaining to Move to Be a Lead Plaintiff in the Shareholder Lawsuit Against Vertex Pharmaceuticals Inc.
9. Amylin Pharmaceuticals Reports First Quarter Financial Results
10. Ferring Pharmaceuticals EUFLEXXA(TM) to Serve as Sponsor for Sprint Force America Masters Track Club
11. Access Pharmaceuticals Announces New Data on Angiolix(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... (PRWEB) July 29, 2014 Gummy smile ... and dark gums treatments that can enhance and perfect ... a balanced appearance that displays the teeth to their best ... gum tissue or have gums that are dark or discolored. ... to feel self-conscious about their smiles or experience a high ...
(Date:7/29/2014)... Kathleen Doheny HealthDay ... Healthy women at low risk of cardiovascular disease may be ... a short time without harming their hearts, according to a ... Initiative, found that hormone replacement therapy had harmful effects on ... they began the hormone treatments, and much further past menopause. ...
(Date:7/29/2014)... (PRWEB) July 29, 2014 iFitDress.com, one of ... its new selection of 2014 high low wedding dresses ... new gowns are offered at discounted prices, up to 68% ... the big discounts before August 05. , The ... of high low wedding dresses. In the new collection, there ...
(Date:7/29/2014)... WA (PRWEB) July 29, 2014 “Approximately ... one of the most common chronic illnesses,” Western Washington ... addressing the need for those suffering from allergies ... spent on allergy-related health care each year in the ... as a mere way of life for themselves, rather ...
(Date:7/29/2014)... "Acceptance, Recognition, and Control (A.R.C.) Against ... own demons and wants other men to heed the call ... A month later, he had no job, leaving Raymond with ... approached the government for assistance, the emotional disturbance was so ... But this approach didn’t get to the root of his ...
Breaking Medicine News(10 mins):Health News:Gummy Smile Surgeon, Dr. Alex Farnoosh, Now Offers Procedures to Improve Gummy Smiles and Dark Gums 2Health News:Early Hormone Therapy May Be Safe for Women's Hearts 2Health News:Early Hormone Therapy May Be Safe for Women's Hearts 3Health News:2014 High Low Wedding Dresses Provided By iFitDress.com 2Health News:Allergy Sufferers are Urged to Seek Medical Help in Recent Article by Western Washington Medical Group 2Health News:Allergy Sufferers are Urged to Seek Medical Help in Recent Article by Western Washington Medical Group 3Health News:SBPRA Announces the Release of Its Newest Title, "Acceptance, Recognition, and Control (A.R.C.) Against Depression" 2
... from Scripps Research Institute, have identified a sensor that identifies ... of glucose. It acts like a switch that increases or ... other times it helps to convert glucose into fat for ... named Liver X Receptor. Its dual function makes it a ...
... largely to the socializing that takes place there, according to ... keeping fit and losing weight but also for meeting new ... Professor of Social Sciences from the University of Manchester, spent ... motivating them to join health clubs. He wanted to study ...
... promises heavy investment opportunities for Non-Resident Keralites (NRK), making ... long term. ,Kerala Tourism Department has ... 23 – 27 for showcasing the opportunities in the ... a congregation of major hospitals, health insurance companies, policy ...
... malnutrition. In spite of hospitalization the survival rate is less ... a research published concerning certain clinical signs that would indicate ... are at greater risk. ,The international group of researchers ... where 920 children were admitted with severe malnutrition between Septemb ...
... A new study provides the strongest evidence yet that a ... testing and risk assessment// for toxins is wrong when it ... ,Edward J. Calabrese, a scientist at the University of Massachusetts ... 56,000 tests in 13 strains of yeast using 2,200 drugs, ...
... has for the first time identified several genes// whose expression ... cancers – lung, breast, prostate and colon cancer. ,The ... genes, is often lost in tumor cells. This can occur ... deletion of the gene. Loss of tumor suppression function also ...
Cached Medicine News:Health News:Glucose Sensor That Controls Glucose Metabolism Identified 2Health News:New Study Challenges How Regulators Determine Risk 2Health News:Profiling of Cancer Genes May Lead to Earlier Detection Human Cancers 2Health News:Profiling of Cancer Genes May Lead to Earlier Detection Human Cancers 3
(Date:7/29/2014)... -- Apex Medical Corporation (Apex, TWSE: 4106), a leading player ... that it is appealing the judgment of the Regional Court ... that found the headgear of certain mask models ... invalidity challenges against various ResMed patents in major countries. Apex ... junk patents. ResMed filed the lawsuit with ...
(Date:7/29/2014)... 29, 2014  Ambit Biosciences (Nasdaq: AMBI ), ... drugs targeting unmet needs in oncology, autoimmune and inflammatory ... results after closing of the NASDAQ Global Market on ... call hosted by Michael Martino , president and ... place on the same day at 5:00 pm EDT ...
(Date:7/29/2014)... , July 29, 2014  The BioFusionary ... on developing a proprietary electromagnetic induction platform with ... into an agreement under which TBC will merge ... Limited (COT) in an all-stock transaction. ... initially trade on the Australian Stock Exchange under ...
Breaking Medicine Technology:Apex Continues Fighting Against Patents to Free Up Competition 2Ambit Biosciences To Announce Second Quarter 2014 Financial Results 2The BioFusionary Corporation, Inc. Announces Intent To Complete Reverse Takeover Of Australia-Based Continuation Investments Limited 2The BioFusionary Corporation, Inc. Announces Intent To Complete Reverse Takeover Of Australia-Based Continuation Investments Limited 3
... Immunomedics, Inc. (Nasdaq: IMMU ) , ... to treat cancer and other serious diseases, today ... Cancers Symposium showed that labetuzumab-SN-38, an antibody-drug conjugate, ... animal models as an effective new therapy. ...
... Fla., Jan. 19 A new approach to unblocking ... down time, lower costs and less risk overall, particularly ... the 21st annual International Symposium on Endovascular Therapy (ISET). ... over bypass surgery to open their blocked arteries. New ...
Cached Medicine Technology:Immunomedics Announces Preclinical Therapy Results of SN-38 Immunoconjugate for Colorectal Cancer 2Immunomedics Announces Preclinical Therapy Results of SN-38 Immunoconjugate for Colorectal Cancer 3Wrist Access Safer, Easier for Many Patients Undergoing Minimally Invasive Treatment of Blocked Heart Arteries 2
1.7% Tryptone, 0.3% Soytone, 0.5% Sodium Chloride, 0.25% Dextrose, 0.25% Potassium Phosphate....
Penicillin G (1 x 10 4 units/mL and Streptomycin (10mg/mL) Solution. 100X Concentrate....
Penicillin-Streptomycin-Glutamine (100X) liquid...
Contains 10,000 units of penicillin (base), 10,000 g of streptomycin (base), and 25 g of amphotericin B/ml utilizing penicillin G (sodium salt), streptomycin sulfate, and amphotericin B as Fungizone ...
Medicine Products: